![]() |
市场调查报告书
商品编码
1309703
胰岛素泵全球市场规模/份额/行业趋势分析报告:产品、适应症、分销渠道(零售店/在线药房、医院药房)、地区的展望和预测,2023-2030Global Insulin Pump Market Size, Share & Industry Trends Analysis Report By Product, By Disease Indication, By Distribution Channel (Retail & Online Pharmacies, and Hospital Pharmacy), By Regional Outlook and Forecast, 2023 - 2030 |
到 2030 年,胰岛素泵市场预计将达到 95 亿美元,预测期内復合年增长率为 9.9%。
根据 KBV 基数矩阵中的分析,F. Hoffmann-La Roche Ltd. 是市场领导者。 2021 年 1 月,F. Hoffmann-La Roche 与 Montmed Inc. 建立合作伙伴关係,为加拿大客户提供 SiteSmart 笔针系统。 此次合作支持罗氏改善糖尿病管理的目标。 Medtronic PLC、Aetna, Inc. 和 Insulet Corporation 等公司是该市场的主要创新者。
新冠肺炎 (COVID-19) 的影响
COVID-19的爆发阻碍了胰岛素泵市场的扩张。 糖尿病诊断和治疗的延迟以及患者购买泵的延迟是促成因素。 此外,在 COVID-19 大流行期间,多个政府制定了法规,中断了泵和消耗品的供应。 例如,美国糖尿病协会报告称,在大流行期间,15% 使用泵或 CGM 的糖尿病患者延迟了补充供应。 由于对该疾病的认识和诊断的提高,预计 2021 年 CGM 和闭环泵的销量将增长 20%。 2020年市场参与者的收入利润率大幅下降。
市场增长因素
全球糖尿病患病率上升
糖尿病在发达国家和新兴国家都变得越来越普遍。 这是多种因素造成的,包括肥胖和久坐的生活方式。 糖尿病事实和数据表明糖尿病对世界各地的人们、家庭和国家来说有多么困难。 根据 IDF 糖尿病地图集(2021 年),10.5% 的成年人(20-79 岁)患有糖尿病,近一半的人根本不知道自己患有糖尿病。 根据 IDF 预测,到 2045 年,八分之一的成年人(即 7.83 亿人)将患有糖尿病,增幅为 46%。 2 型糖尿病是由社会经济、人口、环境和遗传变量驱动的,影响 90% 以上的糖尿病患者。 在预测期内,随着糖尿病患者越来越意识到这些泵和疾病管理的好处,市场预计将会增长。
增加产品发布和批准
随着糖尿病在新兴国家变得更加普遍,市场参与者需要专注于技术改进产品的研发,并将新产品推向市场。 此类研发举措得到了众多临床研究的支持,这些研究表明,与接受 MDI 治疗的 2 型糖尿病患者相比,接受泵治疗的 2 型糖尿病患者的血糖控制持续改善。 因此,预计该市场在未来几年将会增长。
市场製约因素
胰岛素泵通常很昂贵
在预期期间,市场增长预计将受到胰岛素泵高成本的限制。 这些现代药物输送系统正在彻底颠覆传统的医疗保健动态,这也正在改变医疗保健领域。 例如,美国糖尿病协会2019年4月进行的一项研究发现,糖尿病患者的胰岛素泵治疗比MDI治疗更昂贵,价格差异约为43.5%。 此外,与这些泵相关的高额自付费用也阻碍了患者使用它们。
产品展望
按产品划分,市场分为泵和消耗品。 2022年,泵领域占据市场最大的销售份额。 该细分市场的扩张是由于发达国家糖尿病患者越来越多地使用泵。 与多个连续血糖监测仪、每日註射和其他技术相比,这些产品具有多种优势。 据 Tandem 高管称,随着该泵在国内和国际市场上获得关注,预计该泵在 1 型糖尿病患者中的应用将会扩大。
泵类型展望
按泵类型,市场分为贴片泵、系链泵和其他泵。 2022年的市场中,系留式将拥有最高的收入份额。 该细分市场的巨大市场规模主要归功于经典泵的可靠性和广泛的产品阵容。 繫绳泵因其便携性和方便放在口袋里而变得越来越受欢迎。 您还可以使用移动设备轻鬆控制和监测您的血糖水平。 这些优点增加了对繫绳泵的需求。
按适应症划分的展望
按照糖尿病适应症,市场分为 1 型糖尿病和 2 型糖尿病。 2 型糖尿病细分市场将在 2022 年获得显着的市场收入份额。 由于 2 型糖尿病在全球范围内的患病率不断上升,预计该疾病在预测期内将逐渐增长。 越来越多的胰岛素依赖型 2 型糖尿病患者以及从 MDI 转向泵和其他替代治疗的患者也将推动市场扩张。
分销渠道前景
按分销渠道划分,市场分为零售/网上药房和医院药房。 2022年,零售和在线药房领域占据市场最高销售份额。 该市场由零售和在线药房领域推动,该领域占据了市场的很大一部分,因为糖尿病管理设备和解决方案在发达国家和新兴国家的零售店和药店更容易获得。 互联网的日益普及也促进了这一利基市场的扩大。
区域展望
按地区划分,我们对北美、欧洲、亚太地区和拉美地区 (LAMEA) 的市场进行了分析。 2022年,北美地区以最高的收入份额引领市场。 这是由该地区多个主要市场进入者、糖尿病患病率上升以及社会对新给药技术不断增长的需求推动的。 由于可支配收入的增加和健康意识的提高,胰岛素泵的采用率预计将在预测期内保持该地区的领先地位。
The Global Insulin Pump Market size is expected to reach $9.5 billion by 2030, rising at a market growth of 9.9% CAGR during the forecast period.
Asia-Pacific region widely utilizes Insulin Pumps as a sizable portion of the world's population resides in Asia Pacific, and the region's consumers are changing their eating habits, leading to an increase in the number of diabetics. Hence, Asia Pacific captured $1,090.5 million revenue in the market in 2022. Additionally, it is anticipated that in the near future, rising consumer healthcare spending, increased retail pharmacy penetration, and rising health awareness in the region will fuel the expansion of the market in Asia Pacific.
The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In March, 2023, Diabeloop SA entered into a partnership with Novo Nordisk to integrate its 4penTM with Novo Nordisk's reusable and connected insulin pens. The integration of the two offerings would bring better-automated solutions to diabetic patients. Additionally, In June, 2022, SOOIL Developments Co., Ltd partnered with Diabeloop, to integrate their offerings. The interoperability between the offerings would provide customers with better diabetes management solutions.
Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd. is the forerunner in the Market. In January, 2021, F. Hoffmann-La Roche Ltd. entered into a partnership with Montmed Inc. to provide a SiteSmart pen needle system to Canadian customers. The partnership aids Roche in its goal of improving diabetes management. Companies such as Medtronic PLC, Aetna, Inc., Insulet Corporation are some of the key innovators in the Market.
COVID-19 Impact
The COVID-19 outbreak hindered the market expansion for insulin pumps. Delays in diabetes diagnosis and treatment, as well as in patients' purchases of these pumps at this time, were contributing factors. Additionally, during the COVID-19 pandemic, restrictions put in place by several governments resulted in interruptions in the delivery of pumps and supplies. For example, the American Diabetes Association reports that 15% of diabetics who use pumps or CGMs delayed replenishing their supplies during the pandemic. Due to rising disease awareness & diagnosis, CGM and closed-loop pump sales showed a 20% increase in 2021. The revenue margins of the market participants significantly decreased in 2020.
Market Growth Factors
Growing incidence of diabetes globally
Both in developed and emerging nations, diabetes is becoming more common. This is a result of several elements, such as obesity and a sedentary lifestyle. Facts and numbers on diabetes indicate how much of a hardship it is for people, families, and nations worldwide. 10.5% of adults (20-79 years) have diabetes, according to the IDF Diabetes Atlas (2021), and nearly half are completely ignorant that they have the disease. According to IDF predictions, 783 million adults, or one in eight, would have diabetes by 2045, a 46% rise. Type 2 diabetes, caused by socioeconomic, demographic, environmental, and hereditary variables, affects more than 90% of diabetics. During the forecast period, the market is expected to rise due to diabetic patients being more aware of these pumps and the advantages of disease management.
Rising product launches and approvals
The market players are urged to focus on research and development of technologically improved products and introduce new items to the market as the penetration of these pumps among diabetics in emerging nations rises. These R&D initiatives have been supported by numerous clinical studies that demonstrate sustained improvement in glucose control in type 2 diabetic individuals receiving pump therapy as opposed to those receiving MDI therapy. As a result, the market is predicted to grow in the upcoming years.
Market Restraining Factors
Insulin pumps are generally expensive
During the anticipated term, market growth is expected to be constrained by the high cost of insulin pumps. The dynamics of conventional healthcare have been upended by these contemporary drug delivery systems, which have also changed the healthcare sector. For instance, a study conducted by the American Diabetes Association in April 2019 found that insulin pump therapy for diabetic patients is more expensive than MDI therapy, with a price difference of about 43.5%. Also, the greater out-of-pocket costs related to these pumps have discouraged patients from using them.
Product Outlook
On the basis of product, the market is bifurcated into pumps and consumables. In 2022, the pumps segment witnessed the largest revenue share in the market. The segment's expansion results from the diabetic population's rising use of them in industrialized nations. Compared to several continuous glucose monitors, daily injections, and other technologies, these goods provide several advantages. The adoption of pumps among patients with type 1 diabetes is expected to grow as they gain traction in both the domestic and international markets, according to senior Tandem executives.
Pumps Type Outlook
By pumps type, the market is divided into patch, tethered and others. The tethered held the highest revenue share in the market in 2022. The segment's significant market size is primarily attributable to the classic pumps' dependability and the wide range of products available. Due to their portability and convenience, that allow people to carry them in their pockets, tethered insulin pumps have grown in popularity. It may also be easily controlled and used to monitor blood glucose levels via mobile devices. These benefits have led to a rise in the demand for tethered pumps.
Disease Indication Outlook
By diabetes indication, the market is fragmented into Type 1 Diabetes, and Type 2 Diabetes. The Type 2 Diabetes segment garnered a significant revenue share in the market in 2022. Due to the rising prevalence of this condition worldwide, it is also anticipated that the type 2 diabetes segment will grow gradually throughout the course of the projected period. The market's expansion will also be aided by the rising number of type 2 diabetics who are insulin-dependent and by the patients switching from MDIs to pumps and another alternative treatment alternative.
Distribution Channel Outlook
By distribution channel, the market is bifurcated into retail & online pharmacy and hospital pharmacy. In 2022 the retail & online pharmacy segment held the highest revenue share in the market. The retail & online pharmacy segment, which had a sizable portion of the market, led because diabetic management devices &solutions were more readily available in retail & pharmaceutical outlets in developed and developing countries. The growing use of the internet also contributes to the market expansion in this niche.
Regional Outlook
Region wise, the market is analysed across North America, Europe, Asia-Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. This is aided by multiple major market participants in the region, higher diabetes prevalence, and rising public demand for novel medication delivery technologies. The population's adoption of insulin pumps has been prompted by rising disposable income and health awareness, and the region is expected to maintain its leadership during the forecast period.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, F. Hoffmann-La Roche Ltd., Tandem Diabetes Care, Inc., Insulet Corporation, Ypsomed AG, Aetna, Inc. (CVS Pharmacy, Inc.), SOOIL Developments Co., Ltd, Diabeloop SA, Jiangsu Delfu Medical Device Co.,Ltd, and APEX Medical Corporation
Recent Strategies Deployed in Insulin Pump Market
Partnerships, Collaborations, and Agreements:
2023-Mar: Diabeloop SA entered into a partnership with Novo Nordisk, a Danish healthcare company, to integrate its 4penTM with Novo Nordisk's reusable and connected insulin pens. The integration of the two offerings would bring better-automated solutions to diabetic patients.
2022-Nov: Ypsomed AG teamed up with CamDiab, a glucose level management solutions provider, to launch an automated insulin dosing system. The collaboration features the integration of Ypsomed's offerings with CamDiab's adaptive hybrid closed-loop app that would allow Ypsomed to better serve its diabetic patients.
2022-Jun: SOOIL Developments Co., Ltd partnered with Diabeloop, a diabetes management solutions provider, to integrate their offerings. The interoperability between the offerings would provide customers with better diabetes management solutions.
2021-Nov: Diabeloop SA announced a partnership with Terumo Corporation, a medical technology company, to develop solutions for Automated Insulin Delivery. The partnership enhances Diabeloop's position in the European market and would provide its customers with better diabetes care solutions.
2021-Jan: F. Hoffmann-La Roche Ltd. entered into a partnership with Montmed Inc., an Insulin delivery specialist based in Canada, to provide a SiteSmart pen needle system to Canadian customers. The partnership aids Roche in its goal of improving diabetes management.
Mergers & Acquisition:
2023-May: Medtronic PLC acquired EOFlow Co. Ltd., an insulin delivery solutions provider. The acquisition strengthens Medtronic's diabetes management portfolio.
2023-Feb: Insulet Corporation took over the automated insulin delivery assets of Automated Glucose Control LLC, an automated insulin delivery solution provider based in the United States. The acquisition would strengthen the company's ability to deliver automated insulin delivery technology.
2023-Feb: Insulet Corporation announced the acquisition of automated insulin delivery assets of Bigfoot Biomedical, an intelligent injection solutions provider. The acquisition enhances Insulet's IP portfolio.
2023-Jan; Tandem Diabetic Care, Inc. completed the acquisition of AMF Medical SA, an Insulin patch pump manufacturer. The acquisition would enhance the diabetes management expertise of the company by adding a well-experienced team.
Trials and Approvals:
2023-Apr: Medtronic PLC announced the approval by U.S. Food and Drug Administration (FDA) for its MiniMed 780G. The MiniMed 780G is an insulin injector system used when the consumer puts low carbs in their meal.
2023-Apr: The US FDA announced the approval for Insulet Corporation's Omnipod GO, an insulin delivery device used for the treatment of type 2 diabetes.
2022-Feb: Tandem Diabetes Care, Inc. received approval from U.S. Food and Drug Administration for its t:slim X2 insulin pump. The t:slim X2 is used to monitor glucose levels in the patient's body. Additionally, the t:slim X2 can be used along with t:connect mobile app.
Product Launches and Product Expansions:
2022-Nov: Medtronic PLC released the Medtronic Extended infusion set. The infusion set has a wear time of 7 days and uses a tubing connector that would be used for insulin stability.
2021-Mar: Roche has announced the launch of the new Accu-Chek Instant system, a new "connected" blood glucose monitoring (BGM) system, which supports and enables Roche's approach of integrated Personalized Diabetes Management (iPDM). iPDM is a holistic, patient-centered therapeutic approach with the ultimate goal of personalizing diabetes management to streamline care and improve clinical outcomes. iPDM aims to strengthen the care process, facilitates communication between patients and their healthcare team, and integrates tools that visualize and analyze data.
Geographical Expansions:
2022-Jun: Insulet Corporation expanded its geographical footprint by opening a new manufacturing facility in Johor Bahru, Malaysia. The new facility would be used for manufacturing the company's Omnipod Insulin Management System.
Market Segments covered in the Report:
By Product
By Disease Indication
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures